Ad
related to: gcmaf for cancer- Dosing and Admin
View Recommended Dosing and
Administration Information.
- Efficacy & Safety
View Response Data, Study Design,
& Safety Data for Phase 3 Trials.
- Request a Rep
Request a Representative to Learn
More About This Treatment Option.
- Biomarker Testing
See How Testing Reveals a Prevalent
Target for First-Line Treatment.
- Dosing and Admin
Search results
Results from the WOW.Com Content Network
Since around 2008, GcMAF has been promoted as a cure for cancer, [5] HIV, [6] autism [7] and other conditions. [8]Three out of four of the original studies authored by Yamamoto (published between 2007 and 2009) were retracted by the scientific journals in which they were published in 2014, officially due to irregularities in the way ethical approval was granted.
14473 Ensembl ENSG00000145321 ENSMUSG00000035540 UniProt P02774 P21614 RefSeq (mRNA) NM_000583 NM_001204306 NM_001204307 NM_008096 RefSeq (protein) NP_000574 NP_001191235 NP_001191236 NP_032122 Location (UCSC) Chr 4: 71.74 – 71.8 Mb Chr 5: 89.57 – 89.61 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Vitamin D-binding protein (DBP), also/originally known as gc-globulin (g roup ...
David Noakes (born March 1953) [1] is a British computer consultant, [2] businessman and politician, who founded Immuno Biotech Ltd. to promote the unproven therapy GcMAF [3] and came last in the 2006 UKIP leadership election.
This fits in with the goal of providing evidence-based information concerning cancer and cancer treatments. An example of this is the drug GcMAF , which has been promoted as a miracle cure for several illnesses including cancer, but for which those results were never confirmed by independent study.
Kanematsu Sugiura (1890 – October 21, 1979 in White Plains, New York) was a cancer researcher who spent his career at the Memorial Sloan-Kettering Cancer Center. A pioneer in cancer research", [1] he completed over 250 papers before his death. Sugiura received a number of awards and prizes throughout his life, and retired from the center in 1962.
This page was last edited on 19 September 2013, at 13:17 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Most alternative cancer treatments have not been tested in proper clinical trials. Among studies that have been published, the quality is often poor. A 2006 review of 196 clinical trials that studied unconventional cancer treatments found a lack of early-phase testing, little rationale for dosing regimens, and poor statistical analyses. [11]
Hypogammaglobulinemia may result from a variety of primary genetic immune system defects, such as common variable immunodeficiency, [1] or it may be caused by secondary effects such as medication, blood cancer, or poor nutrition, or loss of gamma globulins in urine, as in nonselective glomerular proteinuria.
Ad
related to: gcmaf for cancer